Key Drivers
- Strong Liquidity
- No Revenue
- Heavy Cash Burn
AIAI Summary
AVLN has moved from a survival story to a funded clinical-stage bet: its $138M cash cushion and low debt buy time, but with ~$82M annual free-cash-flow burn, no revenue, and meaningful dilution already baked in, the stock now hinges almost entirely on whether AP01 can deliver credible clinical data before momentum fades.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •No Revenue
- •Heavy Cash Burn
AVLN has exceptionally strong liquidity and minimal debt, but the lack of revenue, heavy R&D-driven losses, and ongoing cash burn make it a highly speculative, pre-commercial company.
Price Behavior
Key Price Behavior Insights:
- •Sharp rebound
- •Resistance stall
- •Support hold
AVLN's sharp rebound remains constructive while it holds above $27.3, but the recent stall near $30.6–$30.8 signals short-term profit-taking and a possible pullback.
Sharp rebound from $18.00 to $29.84, followed by a brief two-session pullback
Sentiment & News
Key News Insights:
- •Upsized IPO
- •Full greenshoe
- •ATS presentations
Avalyn completed an upsized IPO with full greenshoe exercise, signaling strong demand, and also announced upcoming AP01/supportive-care presentations at ATS 2026.
The capital raise likely strengthens Avalyn's funding position while the conference presentations could provide additional clinical visibility for the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings